Hot Investor Mandate: USA-Based Family Office Firm Invests in Early- to Late-Stage Life Science & Healthcare Opportunities, with Strongest Interests in Therapeutics

1 Nov

A family office based in the USA has several decades of experience in investing in life science companies and taking them public. The firm participates in deals across all stages of development, from seed to mezzanine funding. In early-stage deals, the firm’s initial check size is usually between $250-500K, with potential for follow-on financing as the companies achieve key growth milestones. The firm is actively involved with a well-established angel investor group and makes investments through this group as well. The firm is open to opportunities all across the globe.

The firm seeks to invest broadly across different silos of the life sciences ecosystem, from therapeutics, devices, diagnostics, and digital health. The firm’s strongest interest and expertise lies in biotech, and many of the firm’s investments have been in therapeutics companies. The firm is also open to companies of all stages of development and is indication agnostic, but has significantly higher standards for oversaturated, competitive spaces such as oncology.

The firm has no explicitly stated company or management team requirements. The firm likes to become actively involved in their portfolio companies and supports them with needed resources and advisory services to help them grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: